[CAS NO. 913541-47-6] SLX-4090
PRODUCTS SPECIFICATIONS [913541-47-6]
DESCRIPTION [913541-47-6]
Overview
| MDL | MFCD28502203 |
|---|---|
| Molecular Weight | 546.54 |
| Molecular Formula | C31H25F3N2O4 |
| SMILES | O=C(N1CC2=C(C=C(NC(C3=CC=CC(OC)=C3C4=CC=C(C(F)(F)F)C=C4)=O)C=C2)CC1)OC5=CC=CC=C5 |
Summary
SLX-4090 is an orally active enterocytic-specific microsomal triglyceride transfer protein ( MTP ) inhibitor with an IC 50 of 8.0 nM. SLX-4090 can be used for the research of dyslipidemia [1] .
In Vitro
SLX-4090 inhibits apolipoprotein B (IC 50 value 9.6 nM) but not apolipoprotein A1 secretion in Caco-2 cells [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
SLX-4090 (orally, 30 mg/kg) reduces postprandial lipids by 50% with an ED 50 value 7 mg/kg in rats [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00562575 | Kadmon Corporation, LLC |
Hypertriglyceridemia
|
May 2007 | Phase 2 |
| NCT00810979 | Kadmon Corporation, LLC |
Hyperlipidemia
|
January 2009 | Phase 2 |
| NCT00871936 | Kadmon Corporation, LLC |
Type 2 Diabetes
|
April 2009 | Phase 2 |
| NCT01675154 | University of Texas Southwestern Medical Center |
Type 1 Hyperlipoproteinemia
|
November 2015 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 100 mg/mL ( 182.97 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.8297 mL | 9.1485 mL | 18.2969 mL |
| 5 mM | 0.3659 mL | 1.8297 mL | 3.6594 mL |
| 10 mM | 0.1830 mL | 0.9148 mL | 1.8297 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.57 mM); Clear solution